Valuation: DreamCIS, Inc.

Market Cap 96.31B 71.62M 63.94M 58.67M 53.37M 100M 6.78B 102M 701M 282M 3.58B 269M 263M 11.3B P/E 2026 *
9.96x
P/E 2027 * 7.4x
Enterprise Value 53.31M 39.64K 35.39K 32.48K 29.54K 55.39K 3.75M 56.49K 388K 156K 1.98M 149K 146K 6.26M EV / Sales 2026 *
0.59x
EV / Sales 2027 * 0.39x
Free-Float
30.22%
Yield 2026 *
-
Yield 2027 * -
05-14 DreamCIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-23 DreamCIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
12-02 Curi Bio, Inc. announced that it has received $10 million in funding from DreamCIS, Inc. CI
11-11 DreamCIS, Inc. agreed to acquire 13.01% stake in Curi Bio, Inc. CI
11-11 Curi Bio, Inc. announced that it expects to receive $14.848537 million in funding from DreamCIS, Inc. CI
30/09/25 DreamCIS, Inc. announced that it has received KRW 15 billion in funding from Hong Kong Tigermed Co., Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd., Korea Investment & Securities Co., Ltd. CI
22/09/25 DreamCIS, Inc. announced that it expects to receive KRW 15 billion in funding from Hong Kong Tigermed Co., Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd., Korea Investment & Securities Co., Ltd. and other investors CI
22/02/24 Curi Bio, Genetox and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay CI
22/12/23 T&R Biofab Co., Ltd. announced that it has received KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc. CI
14/12/23 T&R Biofab Co., Ltd. announced that it expects to receive KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc. CI
22/03/23 DreamCIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
28/03/22 DreamCIS, Inc. announced that it has received KRW 2.9999925 billion in funding CI
17/03/22 DreamCIS, Inc. announced that it expects to receive KRW 2.9999925 billion in funding CI
1 day-0.38%
1 week+5.86%
Current month-0.38%
1 month+8.16%
3 months+40.46%
6 months-19.70%
Current year-37.70%
1 week 3,800
Extreme 3800
4,200
1 month 3,255
Extreme 3255
4,610
Current year 2,360
Extreme 2360
8,640
1 year 2,360
Extreme 2360
8,640
3 years 2,360
Extreme 2360
8,640
5 years 2,360
Extreme 2360
9,750
10 years 2,360
Extreme 2360
9,750
Manager TitleAgeSince
Chief Executive Officer 56 30/03/2022
Director of Finance/CFO 57 01/05/2016
Chief Operating Officer 56 -
Director TitleAgeSince
Director/Board Member 56 30/03/2022
Director/Board Member 74 31/08/2023
Director/Board Member 59 30/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
12/16/24 A Buy

Chief Executive Officer

30,000 0.1261%
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%+5.86%-7.13%+0.63% 72.71M
+0.79%-2.48%+13.30%+26.51% 113B
-0.25%+3.60%+1.00%+101.95% 97.71B
+2.85%-5.13%+96.62%+811.91% 54.62B
+3.96%+1.17%-6.04%+82.74% 30.65B
+0.10%+7.58%+38.18%+69.48% 28.87B
-0.40%+3.00%+39.70%+86.57% 27.59B
-0.80%+1.97%+32.69%+386.55% 21.4B
-1.28%-5.43%-21.72%-16.73% 19.74B
-1.15%-1.02%-7.07%+29.55% 17.04B
Average +0.33%-0.21%+17.95%+157.92% 41.09B
Weighted average by Cap. +0.64%-1.27%+22.01%+176.89%

Financials

2026 *2027 *
Net sales 90B 66.92M 59.75M 54.83M 49.88M 93.51M 6.34B 95.37M 655M 264M 3.34B 251M 246M 10.56B 117B 86.89M 77.57M 71.19M 64.75M 121M 8.23B 124M 850M 343M 4.34B 326M 319M 13.71B
Net income 9.8B 7.29M 6.51M 5.97M 5.43M 10.18M 690M 10.39M 71.31M 28.74M 364M 27.35M 26.77M 1.15B 13.2B 9.82M 8.76M 8.04M 7.32M 13.71M 929M 13.99M 96.05M 38.72M 490M 36.84M 36.05M 1.55B
Net Debt -43B -31.97M -28.55M -26.2M -23.83M -44.68M -3.03B -45.57M -313M -126M -1.6B -120M -117M -5.05B -51B -37.92M -33.86M -31.07M -28.26M -52.99M -3.59B -54.04M -371M -150M -1.89B -142M -139M -5.99B
Projected Income Statement - Annual - DreamCIS, Inc.
Logo DreamCIS, Inc.
DreamCIS Inc is a Korea-based company principally engaged in the business of contract clinical trial. The Company mainly provides services include regulatory post-marketing surveillance (rPMS), clinical trial, non-interventional study (NIS) and others. The Company provides its services within domestic market and to overseas markets.
Employees
391
Date Price Change Volume
02/11/26 ₩3,975.00 -0.38% 101,854
30/10/26 ₩3,990.00 -0.25% 342,488
29/10/26 ₩4,000.00 +3.36% 207,752
28/10/26 ₩3,870.00 -2.15% 244,495
27/10/26 ₩3,955.00 +5.33% 454,483
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - DreamCIS, Inc.

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - DreamCIS, Inc.
  1. Stock Market
  2. Stocks
  3. A223250 Stock